Abstract
The clinical use of the anticancer drug doxorubicin is limited by severe cardiotoxicity. In mice, the semisynthetic antioxidant flavonoid 7-mono-O-(β-hydroxyethyl)-rutoside (monoHER) has been successfully used as a protector against doxorubicin-induced cardiotoxicity. However, most monoHER has already been cleared from the body at the time that doxorubicin concentrations are still high. This result suggests that not only the parent compound monoHER itself but also monoHER metabolites could be responsible for the observed cardioprotective effects in mice. Therefore, in the present study, we investigated the metabolism of monoHER in mice. Mice were administered 500 mg/kg monoHER intraperitoneally. At different time points after monoHER administration, bile was collected and analyzed for the presence of monoHER metabolites. The formed metabolites were identified by liquid chromatography-diode array detection-time of flight-mass spectrometry. Thirteen different metabolites were identified. The observed routes of monoHER metabolism are methylation, glucuronidation, oxidation of its hydroxyethyl group, GSH conjugation, and hydrolysis of its disaccharide. In line with other flavonoids, methylated monoHER and the monoHER glucosides are expected to have relatively high cellular uptake and low clearance from the body. Therefore, these metabolites might contribute to the observed protection of monoHER against doxorubicin-induced cardiotoxicity.
Footnotes
Article, publication date, and citation information can be found at http://dmd.aspetjournals.org.
doi:10.1124/dmd.110.036525.
-
ABBREVIATIONS:
- monoHER
- 7-mono-O-(β-hydroxyethyl)-rutoside
- LC
- liquid chromatography
- DAD
- diode array detection
- TOF
- electrospray time of flight
- MS
- mass spectrometry
- COMT
- catechol-O-methyltransferase
- SAM
- S-adenosyl-l-methionine
- TFA
- trifluoroacetic acid
- HPLC
- high-performance liquid chromatography
- HP-921
- hexakis-(1H,1H,3H-tetrafluoro-pentoxy)phosphazene
- AUC
- area under the curve
- monoCER
- 7-mono-O-(β-carboxyethyl)-rutoside
- monoHEG
- 7-mono-O-(β-hydroxyethyl)-glucoside
- diHER
- 7-di-O-(β-hydroxyethyl)-rutoside
- triHER
- 7-tri-O-(β-hydroxyethyl)-rutoside
- tetraHER
- 7-tetra-O-(β-hydroxyethyl)-rutoside.
- Received September 29, 2010.
- Accepted January 25, 2011.
- Copyright © 2011 by The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|